You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm is adding data on patient risk for radiographic progression and cardiovascular events to the test, which was recently included in the ACR guidelines.
Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
Doctors can now order the test to identify breast cancer patients with BRCA1/2 mutations who may be eligible for surgery or targeted therapy.
A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.
The company had a challenging fiscal first quarter due to the deletion of CPT codes that payors used to use to reimburse hereditary cancer testing.
Of the 29 companies in the index, 18 companies' share prices declined while the share values of 11 increased month over month.
CMS has attempted to address stakeholders' concerns about its coverage criteria for germline NGS testing in a new proposed national policy.
The drug is now approved as a fourth-line option for advanced, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.